Astragaloside IV

Astragaloside IV has been studied in 22 papers since 2017: none in people yet, 11 in animals, 4 in cells, 7 reviews; 11 in the past year. The research so far is in animals and cells. The newest story, Oct 4, 2026: “Fungus drives spleen aging in mice, eased by astragaloside IV”.

InterventionHuman trials

22 papers study it1 more mentions it45 findingsUpdated

PubChemChEBI

1 new paper in 30 daysSee all 22 papers on astragaloside IV

At a glance

Astragaloside IV extends lifespan in a worm study from one group; independent labs reproduce reduced cellular senescence and oxidative stress in mice. Its papers and grants name the National Natural Science Foundation of China among their funders. A registered trial for a use other than aging ended over a year ago without posted results.

45 findings in 14 papers from 2017 to 2026, 6 of them since April 2026

The findings reach mice, none yet in people; independent labs found the same change in cells and mice. 13 independent labs in 2 countries; 1 trial, none about aging, 1 with no results posted.

None of its findings points the other way.

Cells and mice: replicated by independent labs. Worms or flies: a single group. Humans: nothing yet.
  • 13 independent labs in 2 countries
  • 1 trial, none about aging, 1 with no results posted
  • Funders: National Natural Science Foundation of China and others
  • Animals9
  • Model organisms1
  • Cells4

What did lifespan studies of astragaloside IV find?

DrugAge

DrugAge records 3 results from 1 paper: 3 in C. elegans. Average lifespan is the mean or the median, as each paper reports it.

What did studies of astragaloside IV find?

34

Studies of astragaloside IV measured 34 outcomes, among them cellular senescence, oxidative stress and ROS signaling and inflammation.

Cellular senescence

downin mice3downin human cells1downin rat cells1

5 studies
  1. Astragaloside IV decreases cellular senescence in naturally aged mice and D-galactose-treated H9c2 cells.

    “AS-IV reduced the expression of senescence markers (p16 INK4a , p21, and p53), β-galactosidase (SA-β-gal)”

    Animalsin naturally aged mice and D-galactose-treated H9c2 cells

    Astragaloside IV reduces cardiac aging in mice by restoring mitochondrial balance

    FASEB journal : official publication of the Federation of American Societies for Experimental Biology

  2. Astragaloside IV decreases cellular senescence in hypoxia-reoxygenation-exposed human brain microvascular endothelial cells.

    “AS-IV treatment improved cell viability, reduced oxidative stress (with efficacy comparable to NAC), and downregulated Notch1/VCAM-1, senescence, and SASP markers.”

    Cellsin hypoxia-reoxygenation-exposed human brain microvascular endothelial cells25, 50, or 100 μM

    Astragaloside IV attenuates hypoxia-reoxygenation-induced endothelial senescence and vascular inflammation by modulating the NOTCH1/VCAM-1 axis

    Frontiers in aging neuroscience

  3. Astragaloside IV inhibits cellular senescence in ISO-induced myocardial fibrosis.

    “integrated transcriptomics and proteomics analyses revealed that the anti-MF mechanism of AS-IV was associated with regulating cellular senescence and the p53 signaling pathway.”

    Animalsin ISO-induced myocardial fibrosis

    Integrative transcriptomics and proteomics analysis reveal the protection of Astragaloside IV against myocardial fibrosis by regulating senescence

    European journal of pharmacology

  4. Astragaloside IV decreases cellular senescence in rat cells (high-glucose stress (50 mM)).

    “Pre-treatment of the NPCs with CAG and AG-IV downregulated the protein expression levels of p16, c-C3 and BAX, and decreased the percentage of β-Gal and FITC staining”

    Cellshigh-glucose stress (50 mM)nucleus pulposus

    Cycloastragenol and Astragaloside IV activate telomerase and protect nucleus pulposus cells against high glucose-induced senescence and apoptosis

    Experimental and therapeutic medicine

  5. Astragaloside IV decreases cellular senescence in mice (measured by p16INK4a in ApoE-/- mice).

    “The decreased ki67 and increased p16INK4a in the hearts of ApoE-/- mice were recovered after AST-IV treatment.”

    Animalsmeasured by p16INK4a in ApoE-/- miceheart1 or 10 mg/kg8 weeks

    Astragaloside IV Prevents Cardiac Remodeling in the Apolipoprotein E-Deficient Mice by Regulating Cardiac Homeostasis and Oxidative Stress

    Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology

More on Cellular senescence

Oxidative stress and ROS signaling

downin mice2downin human cells1downin rats1downin reviews1

5 studies
  1. Astragaloside IV decreases oxidative stress and ROS signaling in hypoxia-reoxygenation-exposed human brain microvascular endothelial cells.

    “AS-IV treatment improved cell viability, reduced oxidative stress (with efficacy comparable to NAC), and downregulated Notch1/VCAM-1, senescence, and SASP markers.”

    Cellsin hypoxia-reoxygenation-exposed human brain microvascular endothelial cells25, 50, or 100 μM

    Astragaloside IV attenuates hypoxia-reoxygenation-induced endothelial senescence and vascular inflammation by modulating the NOTCH1/VCAM-1 axis

    Frontiers in aging neuroscience

  2. Astragaloside IV decreases oxidative stress and ROS signaling in rats (ovariectomized rats).

    “AS-IV produced a dose-related improvement in these readouts-CTX-I fell, oxidative stress was eased (SOD increased and MDA decreased), and OCN and PTH moved back toward control levels.”

    Animalsovariectomized ratsgavage8 weeks

    Astragaloside IV modulates oxidative stress and osteoimmune-Wnt signaling in ovariectomized rats: an integrated study of RNA sequencing, molecular docking, and experimental validation

    Frontiers in nutrition

  3. Astragaloside IV inhibits oxidative stress and ROS signaling in ISO-induced myocardial fibrosis.

    “AS-IV treatment markedly attenuated ISO-induced myocardial injury and oxidative stress, concomitantly inhibiting the release of SASPs.”

    Animalsin ISO-induced myocardial fibrosis

    Integrative transcriptomics and proteomics analysis reveal the protection of Astragaloside IV against myocardial fibrosis by regulating senescence

    European journal of pharmacology

  4. Astragaloside IV decreases oxidative stress and ROS signaling.

    “ability of the agent to suppress oxidative stress, to attenuate inflammatory responses and to maintain mitochondrial integrity”

    Review

    Roles and Mechanisms of Astragaloside IV in Combating Neuronal Aging

    Aging and disease

  5. Astragaloside IV decreases oxidative stress and ROS signaling in mice (measured by NOX4-positive cells in ApoE-/- mice).

    “The percentages of apoptotic myocytes and NOX4-positive cells in AST-IV treated mice were decreased”

    Animalsmeasured by NOX4-positive cells in ApoE-/- miceheart1 or 10 mg/kg8 weeks

    Astragaloside IV Prevents Cardiac Remodeling in the Apolipoprotein E-Deficient Mice by Regulating Cardiac Homeostasis and Oxidative Stress

    Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology

More on Oxidative stress and ROS signaling

Inflammation

downin mice1downin reviews1

2 studies
  1. Astragaloside IV decreases inflammation in K. pintolopesii-treated aged mice.

    “disrupting the senescence-inflammation positive feedback loop.”

    Animalsin K. pintolopesii-treated aged micespleen

    Fungus drives spleen aging in mice, eased by astragaloside IV

    Frontiers in immunology

  2. Astragaloside IV decreases inflammation.

    “ability of the agent to suppress oxidative stress, to attenuate inflammatory responses and to maintain mitochondrial integrity”

    Review

    Roles and Mechanisms of Astragaloside IV in Combating Neuronal Aging

    Aging and disease

More on Inflammation

Senescence-associated secretory phenotype (SASP)

downin human cells1downin mice1

2 studies
  1. Astragaloside IV decreases senescence-associated secretory phenotype (SASP) in hypoxia-reoxygenation-exposed human brain microvascular endothelial cells.

    “AS-IV treatment improved cell viability, reduced oxidative stress (with efficacy comparable to NAC), and downregulated Notch1/VCAM-1, senescence, and SASP markers.”

    Cellsin hypoxia-reoxygenation-exposed human brain microvascular endothelial cells25, 50, or 100 μM

    Astragaloside IV attenuates hypoxia-reoxygenation-induced endothelial senescence and vascular inflammation by modulating the NOTCH1/VCAM-1 axis

    Frontiers in aging neuroscience

  2. Astragaloside IV inhibits senescence-associated secretory phenotype (SASP) in ISO-induced myocardial fibrosis.

    “AS-IV treatment markedly attenuated ISO-induced myocardial injury and oxidative stress, concomitantly inhibiting the release of SASPs.”

    Animalsin ISO-induced myocardial fibrosis

    Integrative transcriptomics and proteomics analysis reveal the protection of Astragaloside IV against myocardial fibrosis by regulating senescence

    European journal of pharmacology

More on Senescence-associated secretory phenotype (SASP)

Apoptosis

downin mice1downin rat cells1

2 studies
  1. Astragaloside IV decreases apoptosis in rat cells (high-glucose stress (50 mM)).

    “Pre-treatment of the NPCs with CAG and AG-IV downregulated the protein expression levels of p16, c-C3 and BAX”

    Cellshigh-glucose stress (50 mM)nucleus pulposus

    Cycloastragenol and Astragaloside IV activate telomerase and protect nucleus pulposus cells against high glucose-induced senescence and apoptosis

    Experimental and therapeutic medicine

  2. Astragaloside IV decreases apoptosis in mice (measured by TUNEL in ApoE-/- mice).

    “The percentages of apoptotic myocytes and NOX4-positive cells in AST-IV treated mice were decreased”

    Animalsmeasured by TUNEL in ApoE-/- miceheart1 or 10 mg/kg8 weeks

    Astragaloside IV Prevents Cardiac Remodeling in the Apolipoprotein E-Deficient Mice by Regulating Cardiac Homeostasis and Oxidative Stress

    Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology

More on Apoptosis

SIRT3

upin mouse cells1

1 study
  1. Astragaloside IV activates SIRT3 in mouse cells.

    “AS-IV upregulated SIRT3 and promoted its interaction with DRP1”

    Cells

    Astragaloside IV reduces cardiac aging in mice by restoring mitochondrial balance

    FASEB journal : official publication of the Federation of American Societies for Experimental Biology

More on SIRT3

Mitochondrial function

upin mouse cells1

1 study
  1. Astragaloside IV improves mitochondrial function in mouse cells.

    “AS-IV significantly enhanced mitochondrial morphology and function in cardiomyocytes.”

    Cellscardiomyocytes

    Astragaloside IV reduces cardiac aging in mice by restoring mitochondrial balance

    FASEB journal : official publication of the Federation of American Societies for Experimental Biology

Myocardial fibrosis

downin mice1

1 study
  1. Astragaloside IV decreases myocardial fibrosis in naturally aged mice.

    “significantly ameliorating aging-induced cardiac dysfunction and myocardial fibrosis”

    Animalsin naturally aged miceheart

    Astragaloside IV reduces cardiac aging in mice by restoring mitochondrial balance

    FASEB journal : official publication of the Federation of American Societies for Experimental Biology

More on Myocardial fibrosis

Cardiac dysfunction

downin mice1

1 study
  1. Astragaloside IV decreases cardiac dysfunction in naturally aged mice.

    “significantly ameliorating aging-induced cardiac dysfunction and myocardial fibrosis”

    Animalsin naturally aged miceheart

    Astragaloside IV reduces cardiac aging in mice by restoring mitochondrial balance

    FASEB journal : official publication of the Federation of American Societies for Experimental Biology

Ferroptosis

downin mice1

1 study
  1. Astragaloside IV inhibits ferroptosis in K. pintolopesii-treated aged mice.

    “AGS intervention significantly attenuated KP-associated pathological changes by restoring splenic immune function, modulating iron metabolism and redox homeostasis, suppressing ferroptosis/ferro-aging signaling”

    Animalsin K. pintolopesii-treated aged micespleen

    Fungus drives spleen aging in mice, eased by astragaloside IV

    Frontiers in immunology

More on Ferroptosis

All 34

Has astragaloside IV been tested in people?

0 of 1 about aging

1 trial is registered, but no study of it in people has been published yet.

In trials

Trial sponsors

How this record changed

  1. Summary rewritten as its findings changed.

    As it read before

    In naturally aged mice, astragaloside IV improves cardiac function and decreases myocardial fibrosis. In aged mice challenged with Kazachstania pintolopesii, it reduces splenic inflammation and inhibits ferroptosis.

  2. Summary written from the findings.

Latest

Dec 2025: 1Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 3May 2026: 0Jun 2026: 0Jul 2026: 1Aug 2026: 1Sep 2026: 3Oct 2026: 1Nov 2026: 010 papers in 12 months
Frontiers in Immunology

Fungus drives spleen aging in mice, eased by astragaloside IV

In aged mice, Kazachstania pintolopesii aggravated spleen damage and immune cell ferroptosis, while astragaloside IV treatment restored immune function and iron…In aged mice, Kazachstania pintolopesii aggravated spleen damage and immune cell ferroptosis, while astragaloside IV treatment restored immune function and iron homeostasis.

Experiments in miceInterventions

See all 22 papers on astragaloside IV